Data resource for post-marketing prescription drug abuse surveillance data from individuals entering or being assessed for substance abuse
Award Notice Posted
- Solicitation number
- FDA-RFP-1168334
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Awarded
- to Inflexxion, Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- HHSF223201610027I-75F40118F01004 Federal contract award
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- PSC
- Not on record
Notice details come from SAM.gov. Updated .
Notice text
3 versions
Update #3 · Latest ·
The purpose of this amendment is to make changes to the RFP, Attachment C Pricing Table and Attachment D Past Performance Questionnaire. See attachments for revised documents.
The RFP is hereby amended to include Over-the-Counter Drugs into the scope of the solicitation.
The RFP is hereby amended to reduce the page limitation noted in Section 11 from 25 pages to 10 pages.
The Attachment C excel pricing table is hereby amended to add a, "Data Validation Participation" section to the pricing.
The Attachment D form is hereby changed to include a different version of the past performance questionnaire. Please be advised that submitted copies of the previously posted form will not be accepted.
Update #2 ·
The purpose of this amendment is to make corrections to the deadline for questions in the RFP and correct the point of contact for the past performance questionnaires. The deadline for questions is hereby corrected:
From - July 22, 2016 at 4:00 PM ET
To - June 22, 2016 at 4:00 PM ET
The contact to send past performance questionnaires is hereby revised:
From - william.lee@fda.hhs.gov
To - sean.wybenga@fda.hhs.gov
See attachments for the revised RFP and Past Performance Questionnaire
Update #1 ·
The purpose of this solicitation is to obtain a contract which provides prescription drug abuse summary reports to the U.S. Food and Drug Administration ("FDA"), Center for Drug Evaluation and Research ("CDER"), Office of Surveillance and Epidemiology ("OSE"). In turn, OSE will use the reports to help inform pharmaceutical regulatory and oversight efforts, and abuse prevention programs.
Files
| File | Type | Posted |
|---|---|---|
| Amendment_3_Responses_to_Questions.pdf | ||
| Attachment_D_Past_Performance_Questionnaire_(2).docx | DOCX document | |
| FDA-RFP-1168344_(2).pdf | ||
| Attachment_C_Pricing_Table_(2).xlsx | XLSX spreadsheet | |
| ATTACHMENT_D-_Past-Performance-Questionnaire.doc | DOC document | |
| FDA-RFP-1168334.pdf | ||
| Attachement_A_Glossary.pdf | ||
| FDA-RFP-1168344.pdf | ||
| Attachment_C_Pricing_Table.xlsx | XLSX spreadsheet | |
| ATTACHMENT_B_DATA_CHARACTERISTICS_TABLE.pdf | ||
| ATTACHMENT_D-_Past-Performance-Questionnaire.doc | DOC document |
Show all 11
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity